The Medical Letter - 2015
Year:    Publication:      2015 Annual Index: U.S. English | Canadian English
January 5, 2015 (Issue 1459)  
January 19, 2015 (Issue 1460)  
February 2, 2015 (Issue 1461)  
February 16, 2015 (Issue 1462)  
  • Diet, Drugs, and Surgery for Weight Loss
    Superseded by The Medical Letter "Diet, Drugs, Devices, and Surgery for Weight Management" - Issue 1548, June 4, 2018Adults with a body mass index (BMI) between 25 and 29.9 kg/m2...
March 2, 2015 (Issue 1463)  
  • Suvorexant (Belsomra) for Insomnia
    The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
  • Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
    The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated...
  • An Inhaled Insulin (Afrezza)
    The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin (Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In...
  • Tavaborole Topical Solution (Kerydin) for Onychomycosis
    The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton...
  • Correction: Secondary Prevention of Stroke
    In the article on Secondary Prevention of Stroke in the December 8, 2014 issue of The Medical Letter (volume 56, page 125), the duration of treatment with clopidogrel plus aspirin in patients who...
March 16, 2015 (Issue 1464)  
  • Drugs for ADHD
    Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently...
  • VEGF Inhibitors for AMD and Diabetic Macular Edema
    Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and...
  • In Brief: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder
    Lisdexamfetamine dimesylate (Vyvanse), a prodrug of dextroamphetamine previously approved for treatment of attention-deficit/hyperactivity disorder, has now been approved for treatment of...
March 30, 2015 (Issue 1465)  
  • Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
    The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and...
  • Secukinumab (Cosentyx) for Psoriasis
    Secukinumab (Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult...
  • Gardasil 9 - A Broader HPV Vaccine
    The FDA has now approved a recombinant, 9-valent, human papillomavirus (HPV) vaccine (Gardasil 9 – Merck) for use in girls and women 9-26 years old and boys 9-15 years old. The new...
  • OTC Fluticasone Nasal Spray for Allergic Rhinitis
    The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription...
  • Spiriva Respimat - An Oral Inhalation Spray for COPD
    Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary...
April 13, 2015 (Issue 1466)  
  • Ivermectin Cream (Soolantra) for Rosacea
    The FDA has approved a 1% cream formulation of the antiparasitic drug ivermectin (Soolantra – Galderma) for topical treatment of inflammatory lesions of rosacea. Ivermectin is available...
  • Advice for Travelers
    Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on...
  • In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone
    The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially...
April 27, 2015 (Issue 1467)  
May 11, 2015 (Issue 1468)  
May 25, 2015 (Issue 1469)  
June 8, 2015 (Issue 1470)  
  • Drugs for Psoriasis
    Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical...
  • Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
    The FDA has approved nivolumab (Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed...
  • Recombinant Human Parathyroid Hormone (Natpara)
    The FDA has approved a subcutaneously injected formulation of recombinant human parathyroid hormone (Natpara – NPS) as an adjunct to calcium and vitamin D to control hypocalcemia in...
  • Drugs for Psoriatic Arthritis (online only)
    Psoriatic arthritis is a chronic inflammatory arthropathy that develops in up to 40% of patients with psoriasis. Several guidelines for treatment of psoriatic arthritis have been published.
June 22, 2015 (Issue 1471)  
  • Liraglutide (Saxenda) for Weight Loss
    The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza, has now also been approved at a...
  • Which PPI?
    An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor...
  • Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
    The FDA has approved droxidopa (Northera – Lundbeck) for oral treatment of adults with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure...
  • Bellafill for Acne Scars
    Bellafill (Suneva), a dermal filler approved earlier for correction of nasolabial folds, has now also been approved by the FDA for correction of moderate to severe, atrophic, distensible...
  • In Brief: Ketoacidosis with SGLT2 Inhibitors
    The FDA has warned that use of an SGLT2 (sodium-glucose co-transporter 2) inhibitor for treatment of type 2 diabetes may lead to ketoacidosis.1 Three SGLT2 inhibitors, canagliflozin (Invokana,...
  • Addendum: Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
    After our article on nivolumab (Opdivo – BMS) for treatment of metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) was published in the most recent issue of...
July 6, 2015 (Issue 1472)  
July 20, 2015 (Issue 1473)  
August 3, 2015 (Issue 1474)  
August 17, 2015 (Issue 1475)  
  • Alirocumab (Praluent) to Lower LDL-Cholesterol
    The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab (Praluent – Sanofi/Regeneron) as an adjunct to diet and...
  • Palbociclib (Ibrance) for Metastatic Breast Cancer
    Palbociclib (Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole (Femara, and...
  • Brexpiprazole (Rexulti) for Schizophrenia and Depression
    The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants...
  • In Memoriam
    July was a sad month at The Medical Letter.Hans Meinertz, M.D. of University Hospital in Copenhagen died on July 21, 2015. Hans joined the Advisory Board of The Medical Letter in...
  • Panobinostat (Farydak) for Multiple Myeloma (online only)
    The FDA has approved panobinostat (Farydak – Novartis), an oral histone deacetylase (HDAC) inhibitor, for use in combination with bortezomib (Velcade) and dexamethasone for...
  • Lenvatinib (Lenvima) for Thyroid Cancer (online only)
    The FDA has approved the oral multikinase inhibitor lenvatinib (Lenvima – Eisai) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary...
August 31, 2015 (Issue 1476)  
September 14, 2015 (Issue 1477)  
  • Influenza Vaccine for 2015-2016
    Superseded by The Medical Letter "Influenza Vaccine for 2018-2019" - Issue 1558, October 22, 2018Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months...
  • Choice of Contraceptives
    Superseded by The Medical Letter "Choice of Contraceptives" - Issue 1557, October 8, 2018Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods...
September 28, 2015 (Issue 1478)  
October 12, 2015 (Issue 1479)  
  • SGLT2 Inhibitors: New Reports
    The recent report of a reduction in cardiovascular mortality in patients with type 2 diabetes treated with the SGLT2 inhibitor empagliflozin (Jardiance) was published soon after the FDA...
  • Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
    Evolocumab (Repatha – Amgen), a subcutaneously injected PCSK9 inhibitor, has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for adults with...
  • Daclatasvir (Daklinza) for HCV Genotype 3 Infection
    The FDA has approved daclatasvir (Daklinza – BMS), an oral direct-acting antiviral drug, for use with sofosbuvir (Sovaldi) for treatment of chronic hepatitis C virus (HCV)...
  • Eloctate for Hemophilia A
    The FDA has approved Eloctate (Biogen), a recombinant factor VIII Fc fusion protein with an extended half-life, for use in adults and children with hemophilia A. Eloctate is...
  • Addendum: PCV13 for Adults 65 Years and Older
    In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the...
October 26, 2015 (Issue 1480)  
November 9, 2015 (Issue 1481)  
November 23, 2015 (Issue 1482)  
December 7, 2015 (Issue 1483)  
December 21, 2015 (Issue 1484)